Posting on behalf of Prof. Alessio Ciulli: Professor Alessio Ciulli’s laboratory is seeking a postdoctoral researcher to undertake research in collaboration with one of the leading pharmaceutical companies supporting the Division of Signal Transduction Therapy (DSTT). The DSTT facilitates collaborations between some of the world’s major pharmaceutical companies (Boehringer Ingelheim, GlaxoSmithKline, and Merck-Serono) and leading Dundee-based researchers with a proven track record of achievement in understanding and exploiting the fundamental molecular causes of human disease in the fields of cancer, immune-regulation, neurodegeneration and hypertension resulting from disruptions in protein ubiquitylation, phosphorylation and other signalling networks. The successful applicant will be based within the Ciulli lab in Dundee ( http://www.lifesci.dundee.ac.uk/groups/alessio-ciulli). The laboratory is pioneering novel chemical structural biology approaches to target E3 ubiquitin ligases with small molecules. The applicant will employ state of the art structural biology, cell biology and biophysical approaches to conduct molecular and structural studies on disease-relevant human E3 ubiquitin ligases. The Ciulli lab has close collaborations and access to facilities available within both the MRC Protein Phosphorylation Unit ( http://www.ppu.mrc.ac.uk/) and more widely within the School of Life Sciences. This set-up will ensure the successful candidate will have access to whatever technologies required to conduct the projects that they are working on, including molecular, biochemical, mass spec proteomics, pharmacological and genetic methodologies including CRISPR/CAS9 knock-out and knock-in technologies. There will be regular opportunity for interaction and to discuss data within the group and with the collaborating pharma company. Candidate requirements: ‧ PhD with outstanding academic track record and at least one first authored publication in an internationally recognised peer-reviewed journal. ‧ Strong background in Biochemistry, Molecular Cell Biology, or Structural Biology is required. ‧ Strong interest in signal transduction research and how disruptions of these pathways are linked to human disease is expected. ‧ Experience with recombinant protein expression and purification, molecular cloning, and protein X-ray crystallography (or cryo-EM) is required. ‧ Experience with mammalian cells tissue culture, and protein-protein interaction studies inside cells e.g. pull-down, proteomics, would be highly advantageous. ‧ Experience with biophysical methods to study in vitro protein-protein and protein-peptide interactions is desirable. ‧ Capable of working in a team, but able to plan and work independently. ‧ Excellent communication skills and knowledge of the English language are essential. ‧ The candidate should have ambitions to become a successful independent researcher either in academia or the pharmaceutical/biotechnology industry. The fund for this project is available till 30th June 2020 in the first instance with a chance to renew. For informal enquiries please contact Prof Alessio Ciulli [email protected] or Dr Kwok-Ho Chan [email protected] Closing Date 31 May 2019 Job details: https://ig5.i-grasp.com/fe/tpl_uod01.asp?newms=jj&id=103176&newlang=1